학술논문
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours
Document Type
Article
Author
Source
In European Journal of Cancer November 2017 86:240-247
Subject
Language
ISSN
0959-8049